Ipamorelin / CJC-1295 10 mg

What it is

Ipamorelin is a selective growth-hormone secretagogue receptor agonist; CJC-1295 is a growth-hormone-releasing-hormone analogue. Combined presentations are supplied as research chemicals and are not approved medicines.

Mechanism being studied

Both act on pathways that influence pulsatile growth-hormone release in laboratory and animal studies.

Human evidence

Some early-phase pharmacokinetic studies exist for the individual compounds, but there is no adequate controlled evidence for the combination in general clinical use, and no approved indication.

Safety considerations

Manipulating endocrine axes carries meaningful clinical risk, including effects on glucose regulation, fluid balance and hormone-sensitive conditions. Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.

Regulatory status

Not approved medicines. Prohibited in sport by WADA. Confirm local supply rules.

Certificate of analysis

Third-party analytical documentation for this compound is published for transparency and professional review. It confirms identity and purity of tested material only, and is not a marketing authorisation, a registration, or a recommendation for use.

Key references

• Endocrinology peer-reviewed literature on GH secretagogues.
• World Anti-Doping Agency Prohibited List (S2).

References are provided as reading directions for professionals. They do not constitute endorsement of any use.